Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 6/20 | 0.44 |
| ▸ | CSF1R | P07333 | 4/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26101448 | 0.93 | KIT (0.44) | KITPDGFRAPDGFRBEGFRAURKA | |
| SCHEMBL26101800 | 0.93 | EGFR (0.52) | KITPDGFRAEGFRKDR | |
| SCHEMBL26101259 | 0.91 | EGFR (0.44) | KITPDGFRAPDGFRBEGFRFLT3 | |
| SCHEMBL26101324 | 0.90 | EGFR (0.44) | KITPDGFRAPDGFRBEGFRFLT3 | |
| SCHEMBL29238223 | 0.90 | PDGFRB (0.44) | KITPDGFRBEGFRAURKAFLT3 | |
| SCHEMBL29238608 | 0.89 | KIT (0.45) | KITPDGFRAPDGFRBEGFRFLT3 | |
| SCHEMBL26101555 | 0.87 | KIT (0.42) | KITPDGFRAPDGFRBEGFRFLT3 | |
| SCHEMBL26102213 | 0.86 | EGFR (0.54) | KITPDGFRAPDGFRBEGFRAURKA | |
| SCHEMBL26103039 | 0.85 | EGFR (0.50) | KITPDGFRBEGFRFLT3CSF1R | |
| SCHEMBL30394281 | 0.84 | EGFR (0.52) | KITPDGFRBEGFRFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | claimed |
| CN-118201909-A | Quinazoline derivative compound and use thereof | 株式会社沃若诺伊 | 2024-06-14 | — | — | CN | claimed |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | KIT 2/4885PDGFRA 1/4885PDGFRB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.